|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:approvedBy
|
1965
|
|
gptkbp:ATCCode
|
N05BA04
|
|
gptkbp:brand
|
gptkb:Alepam
gptkb:Ox-Pam
gptkb:Serax
Murelax
|
|
gptkbp:CASNumber
|
604-75-1
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
severe respiratory insufficiency
sleep apnea syndrome
hypersensitivity to benzodiazepines
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:discoveredBy
|
gptkb:Wyeth_Pharmaceuticals
|
|
gptkbp:drugClass
|
benzodiazepine
sedative
anticonvulsant
muscle relaxant
hypnotic
|
|
gptkbp:eliminationHalfLife
|
5-15 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C15H11ClN2O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oxazepam
|
|
gptkbp:IUPACName
|
gptkb:7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:meltingPoint
|
162–163 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
gptkb:C_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
85–95%
|
|
gptkbp:PubChem_CID
|
4615
4455
|
|
gptkbp:relatedTo
|
gptkb:lorazepam
gptkb:diazepam
gptkb:temazepam
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
drowsiness
ataxia
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:synonym
|
gptkb:3-hydroxy-diazepam
|
|
gptkbp:UNII
|
YHH6D5JT0T
|
|
gptkbp:usedFor
|
insomnia
anxiety disorders
alcohol withdrawal
|
|
gptkbp:bfsParent
|
gptkb:benzodiazepine
|
|
gptkbp:bfsLayer
|
6
|